![Mark de Boer](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mark de Boer
Amministratore Delegato presso Fast Forward Pharmaceuticals BV
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Karin Laglas | F | 64 |
University of Utrecht
| - |
Mark Throsby | M | 57 |
Gadeta BV
![]() Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | 4 anni |
Jan van de Winkel | M | 63 |
University of Utrecht
| 28 anni |
Henk Kummeling | M | - |
University of Utrecht
| - |
Albert Osterhaus | M | - |
University of Utrecht
| - |
Giovanni Mariggi | M | 39 |
Gadeta BV
![]() Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | - |
Edwin Cuppen | M | - |
University of Utrecht
| - |
Marcel Zwaal | M | - |
Gadeta BV
![]() Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | 3 anni |
Lambert Meertens | M | - |
University of Utrecht
| - |
Martin J. M. Tielen | M | 81 |
University of Utrecht
| - |
Nico Vandervelpen | M | 49 |
Fast Forward Pharmaceuticals BV
![]() Fast Forward Pharmaceuticals BV Medical SpecialtiesHealth Technology Fast Forward Pharmaceuticals BV develops novel disease-modifying therapeutics for the treatment of inflammatory and autoimmune diseases. It is developing an anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The company was founded by Louis Boon in October 2010 and is headquartered in Utrecht, Netherlands. | - |
J. P. Bahlmann | M | 74 |
University of Utrecht
| - |
Steven R. Schuit | M | 81 |
University of Utrecht
| - |
Jeroen F. J. M. de Haas | M | 65 |
University of Utrecht
| - |
Jan M. van der Eijk | M | 64 |
University of Utrecht
| - |
Hans Clevers | M | 67 |
University of Utrecht
| 35 anni |
Guus Scheefhals | M | 64 |
Crossbeta Biosciences BV
![]() Crossbeta Biosciences BV BiotechnologyHealth Technology Crossbeta Biosciences BV develops drug discovery programs in the area of misfolded protein diseases. It specializes in alzheimer's disease drug development and drug discovery platform services. The company was founded by Martijn Gebbink and Barend Bouma in 2005 and is headquartered in Utrecht, the Netherlands. | 14 anni |
Joost J. M. Holthuis | M | 71 |
Crossbeta Biosciences BV
![]() Crossbeta Biosciences BV BiotechnologyHealth Technology Crossbeta Biosciences BV develops drug discovery programs in the area of misfolded protein diseases. It specializes in alzheimer's disease drug development and drug discovery platform services. The company was founded by Martijn Gebbink and Barend Bouma in 2005 and is headquartered in Utrecht, the Netherlands. | 11 anni |
Hans J. W. de Haard | M | 64 |
University of Utrecht
| - |
René Bernards | M | 72 |
University of Utrecht
| - |
Margot van der Starre | F | - |
University of Utrecht
| - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Jeffrey L. Cleland | M | 59 |
Versartis, Inc.
![]() Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | 7 anni |
Edmon R. Jennings | M | 75 |
Versartis, Inc.
![]() Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | 6 anni |
Willem P. C. Stemmer | M | - |
Versartis, Inc.
![]() Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | - |
Mohammed Malik | M | 56 |
Versartis, Inc.
![]() Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | - |
Volker Schellenberger | M | - |
Versartis, Inc.
![]() Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | - |
Paul B. Westberg | M | 56 |
Versartis, Inc.
![]() Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | - |
Joshua Silverman | M | - |
Versartis, Inc.
![]() Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | - |
Sharon Longhurst | M | 55 |
Gadeta BV
![]() Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | 2 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Paesi Bassi | 22 | 75.86% |
Stati Uniti | 7 | 24.14% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Mark de Boer
- Contatti personali